Alnylam Pharmace. buy Evercore ISI
Start price
25.06.24
/
50%
€221.10
Target price
25.06.25
€242.92
Performance (%)
25.69%
End price
26.06.25
€277.90
Summary
This prediction ended on 26.06.25 with a price of €277.90. The prediction had a final performance of 25.69%. Evercore_ISI has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Evercore_ISI has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -0.279% | -0.279% | -50.089% |
| iShares Core DAX® | -1,59 % | 5,03 % | 6,33 % |
| iShares Nasdaq 100 | -4,15 % | -0,13 % | 25,73 % |
| iShares Nikkei 225® | -6,30 % | 0,53 % | 41,38 % |
| iShares S&P 500 | -3,23 % | 0,47 % | 20,45 % |
Comments by Evercore_ISI for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Evercore ISI from $210.00 to $260.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Evercore_ISI gewählte maximale Laufzeit wurde überschritten
Current prediction by Evercore_ISI for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€399.10
11.09.25
11.09.25
€440.26
11.09.26
11.09.26
-50.79%
20.08.26
20.08.26
